Adequate Control of Low-Density Lipoprotein Cholesterol (LDL-C) for Diabetic and Non-Diabetic Cases

For atherosclerotic cardiovascular disease (ASCVD), adequate control of low-density lipoprotein cholesterol (LDL-C) would be required. Discussion have been found concerning LDL-C borderline as 55, 70 or 100mg/dL by American College of Cardiology (ACC), American Heart Association (AHA) and European Heart Association (EHA). Latest study was reported from PEMA-study with 523 cases of diabetic (n=277) and non-diabetic (n=246). The protocol included the influence of LDL-C on the existence of plaque, using intravascular ultrasonography and near-infrared spectroscopy. As a result, targeting LDL-C <55 mg/dL would be effective for stabilizing plaques in non-diabetic, while it would be less effective in diabetic cases.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.